These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37855293)

  • 1. Targeting Various Pathogenic Pathways for the Development of Antialzheimer's Drugs: An Update.
    Ambreen S; Fatima N; Umar M; Shaququzzaman M; Alam MM; Ali R
    Curr Top Med Chem; 2023 Oct; ():. PubMed ID: 37855293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frontiers in the pathogenesis of Alzheimer's disease.
    Sambamurti K; Jagannatha Rao KS; Pappolla MA
    Indian J Psychiatry; 2009 Jan; 51 Suppl 1(Suppl1):S56-60. PubMed ID: 21416019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Novel microRNAs in Developing Novel Alzheimer's Disease Treatments.
    Seyedaghamiri F; Rajabi M; Mohaddes G
    Neurochem Res; 2023 Jan; 48(1):26-38. PubMed ID: 36048350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intracerebral seeding of amyloid-β and tau pathology in mice: Factors underlying prion-like spreading and comparisons with α-synuclein.
    McAllister BB; Lacoursiere SG; Sutherland RJ; Mohajerani MH
    Neurosci Biobehav Rev; 2020 May; 112():1-27. PubMed ID: 31996301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug Discovery to Drug Development of BACE1 Inhibitor as Antialzheimer's: A Review.
    Munj SM; Patil PB
    Curr Top Med Chem; 2023; 23(2):77-97. PubMed ID: 36579387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amyloid precursor protein, presenilins, and alpha-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer's disease.
    Suh YH; Checler F
    Pharmacol Rev; 2002 Sep; 54(3):469-525. PubMed ID: 12223532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prions and Neurodegenerative Diseases: A Focus on Alzheimer's Disease.
    Crestini A; Santilli F; Martellucci S; Carbone E; Sorice M; Piscopo P; Mattei V
    J Alzheimers Dis; 2022; 85(2):503-518. PubMed ID: 34864675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Status and future directions of clinical trials in Alzheimer's disease.
    Plascencia-Villa G; Perry G
    Int Rev Neurobiol; 2020; 154():3-50. PubMed ID: 32739008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular and functional signatures in a novel Alzheimer's disease mouse model assessed by quantitative proteomics.
    Kim DK; Park J; Han D; Yang J; Kim A; Woo J; Kim Y; Mook-Jung I
    Mol Neurodegener; 2018 Jan; 13(1):2. PubMed ID: 29338754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer's Disease: A Focus on Aducanumab and Lecanemab.
    Shi M; Chu F; Zhu F; Zhu J
    Front Aging Neurosci; 2022; 14():870517. PubMed ID: 35493943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining in vitro and in silico Approaches to Find New Candidate Drugs Targeting the Pathological Proteins Related to the Alzheimer's Disease.
    Li H; Wang X; Yu H; Zhu J; Jin H; Wang A; Yang Z
    Curr Neuropharmacol; 2018; 16(6):758-768. PubMed ID: 29086699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sigma ligands as potent inhibitors of Aβ and AβOs in neurons and promising therapeutic agents of Alzheimer's disease.
    Ma WH; Chen AF; Xie XY; Huang YS
    Neuropharmacology; 2021 Jun; 190():108342. PubMed ID: 33045243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aβ-induced acceleration of Alzheimer-related τ-pathology spreading and its association with prion protein.
    Gomes LA; Hipp SA; Rijal Upadhaya A; Balakrishnan K; Ospitalieri S; Koper MJ; Largo-Barrientos P; Uytterhoeven V; Reichwald J; Rabe S; Vandenberghe R; von Arnim CAF; Tousseyn T; Feederle R; Giudici C; Willem M; Staufenbiel M; Thal DR
    Acta Neuropathol; 2019 Dec; 138(6):913-941. PubMed ID: 31414210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue transglutaminase, protein cross-linking and Alzheimer's disease: review and views.
    Wang DS; Dickson DW; Malter JS
    Int J Clin Exp Pathol; 2008 Jan; 1(1):5-18. PubMed ID: 18784819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Key Peptides and Proteins in Alzheimer's Disease.
    Penke B; Bogár F; Paragi G; Gera J; Fülöp L
    Curr Protein Pept Sci; 2019; 20(6):577-599. PubMed ID: 30605056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Linking the Amyloid, Tau, and Mitochondrial Hypotheses of Alzheimer's Disease and Identifying Promising Drug Targets.
    Fišar Z
    Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36421690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of Alzheimer Disease Neuropathologic Staging with Amyloid and Tau Scintigraphic Imaging Biomarkers.
    Koychev I; Hofer M; Friedman N
    J Nucl Med; 2020 Oct; 61(10):1413-1418. PubMed ID: 32764121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amyloid-beta aggregation implicates multiple pathways in Alzheimer's disease: Understanding the mechanisms.
    Iliyasu MO; Musa SA; Oladele SB; Iliya AI
    Front Neurosci; 2023; 17():1081938. PubMed ID: 37113145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble pre-fibrillar tau and β-amyloid species emerge in early human Alzheimer's disease and track disease progression and cognitive decline.
    Koss DJ; Jones G; Cranston A; Gardner H; Kanaan NM; Platt B
    Acta Neuropathol; 2016 Dec; 132(6):875-895. PubMed ID: 27770234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.